Archive for the ‘Featured’ Category

Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation

Posted by Michael A. S. Guth on April 30th, 2026

https://doi.org/10.1016/j.drudis.2026.104678  Free download of the article using this link until June 16:  https://authors.elsevier.com/a/1n0uP4r9Rkz1l6 Highlights New four-pillar framework accelerates deorphanization of dark GPCR targets. (77 chars) GPR149 structural analysis identifies non-canonical ERY and DPxxF motifs. (76 chars) Path-agnostic screening bypasses traditional Gi/o signaling limitations. (75 chars) Integrated CNS and metabolic mapping reveals GPR149′s dual-domain value. (76 chars) […]

Posted in About, Featured, Neuroplasticity Comments Off on Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation
Read More »

In the 1950s, my physicist father met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.

Posted by Michael A. S. Guth on April 5th, 2026

In the 1950s, my physicist father, Eugene Guth, met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory. Einstein, it turned out, was more interested in the philosophy of physics than the math, a topic equally of interest to my dad.  See https://michaelguth.com/family/HistoryofPhysicsbyEugeneGuth.htm Mathematics and philosophy of physics have relevance […]

Posted in About, Featured, Neuroplasticity, Pharma and Medical Device Comments Off on In the 1950s, my physicist father met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.
Read More »

Authority, Long-term Reach, and “Save” Signals

Posted by Michael A. S. Guth on March 24th, 2026

New evidence provides a stronger link between chronic anxiety and future neurocognitive decline, demanding a re-evaluation of how we approach dementia prevention in clinical practice. A major updated meta-analysis, now available in the Journal of Clinical Medicine, confirms that anxiety is significantly associated with an increased risk of all-cause dementia. This extensive study, spanning nine […]

Posted in Featured, Neuroplasticity, Regulatory Medical Writing Comments Off on Authority, Long-term Reach, and “Save” Signals
Read More »

𝐓𝐡𝐞 “𝐒𝐡𝐚𝐩𝐞” 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐖𝐡𝐲 𝐌𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐫𝐬 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐑𝐖𝐄 𝐢𝐧 𝐂𝐍𝐒

Posted by Michael A. S. Guth on February 23rd, 2026

𝐇𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 𝐓𝐡𝐞 “𝐒𝐡𝐚𝐩𝐞” 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐖𝐡𝐲 𝐌𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐫𝐬 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐑𝐖𝐄 𝐢𝐧 𝐂𝐍𝐒 In the high-stakes world of CNS drug discovery and Real-World Evidence (RWE), we’ve leaned on behavioral scales for too long. But in 2026, the data is clear: Morphological Biomarkers are the new gold standard. Recent advancements in Geometric Morphometrics prove […]

Posted in Featured, Neuroplasticity Comments Off on 𝐓𝐡𝐞 “𝐒𝐡𝐚𝐩𝐞” 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐖𝐡𝐲 𝐌𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐫𝐬 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐑𝐖𝐄 𝐢𝐧 𝐂𝐍𝐒
Read More »

Beyond the BBB: Mapping the 2026 Milestone Year for Neuroscience

Posted by Michael A. S. Guth on February 18th, 2026

Beyond the BBB: Mapping the 2026 Milestone Year for Neuroscience.  As we move through Q1, all eyes in the neuroscience community are on April 5, 2026—the PDUFA target action date for tividenofusp alfa (DNL310). If approved, tividenofusp alfa will be a watershed moment: the first commercial validation of a Transport Vehicle (TV) enabled enzyme replacement […]

Posted in Featured, Regulatory Medical Writing Comments Off on Beyond the BBB: Mapping the 2026 Milestone Year for Neuroscience
Read More »

“Chemo Brain” and Diabetes Research

Posted by Michael A. S. Guth on February 10th, 2026

Is the Next Breakthrough in “Chemo Brain” Treatment Hiding in Diabetes Research? For cancer survivors, the battle often doesn’t end with remission. Chemotherapy-Induced Cognitive Impairment (CICI)—widely known as “Chemo Brain”—remains one of the most debilitating long-term side effects of treatment, affecting memory, executive function, and attention. While the clinical impact is well-documented, therapeutic options remain […]

Posted in Featured, Neuroplasticity, Pharma and Medical Device Comments Off on “Chemo Brain” and Diabetes Research
Read More »

COVID-19 Treatment Strategies: Dec 2025 update

Posted by Michael A. S. Guth on December 13th, 2025
Moving Simulation of SARS-CoV-2 Delta Variant

Image:  Computer Simulation of SARS-CoV-2. Reprinted with kind permission of Janet Iwasa of http://animationlab.utah.edu/cova Should I Get a COVID-19 Vaccine in December 2025 or January 2026? As we move through the winter of 2025-2026, the question of whether to get a COVID-19 vaccine is highly relevant, especially as respiratory viruses typically peak during this time. The […]

Posted in Featured, Pharma and Medical Device Tags: , , , , , , , , , Comments Off on COVID-19 Treatment Strategies: Dec 2025 update
Read More »

The State of Cancer Research

Posted by Michael A. S. Guth on August 7th, 2021

And we already know how small a role the cancer gene plays in the onset of cancer: there has been an 8-fold to 17-fold increase in the incidence of cancer in the last hundred years, but not even one-millionth of 1 percent of that increase can be related to genes.

Genes evolve over hundreds of thousands (if not millions) of years, which means that the so-called cancer gene has had no impact on the huge increase we’ve seen since 1900. Virtually 90 percent of the cancer that we see today cannot possibly have anything to do with genes.

Posted in Featured Tags: , , Comments Off on The State of Cancer Research
Read More »

Clinical Evaluation Report (CER) Medical Writer

Posted by Michael A. S. Guth on March 15th, 2020

Perform Clinical Evaluations and write/update Clinical Evaluation Reports (CERs) and Clinical Evaluation Plans (CEPs)  in compliance with the European Union (EU) Medical Device Regulation (MDR).  Perform Literature Reviews using PubMed, Embase, Cochrane Library, and similar databases. Interpret the current, new, and changing requirements for clinical research—including heightened restrictions on product equivalency—to ensure the proper clinical […]

Posted in Featured, Regulatory Medical Writing Comments Off on Clinical Evaluation Report (CER) Medical Writer
Read More »

Combining Research, Safety, and Epidemiology

Posted by Michael A. S. Guth on October 23rd, 2018

Risk Management Consulting (RMC), a health services research firm, offers Research, Safety, and Epidemiology services with experience in the healthcare consulting and biopharmaceutical industries. RMC provides the health care system, biopharmaceutical industry, academia, and the Federal Government with “real-world” data to improve the quality, safety, and affordability of healthcare. RMC’s projects range from retrospective to […]

Posted in Featured, Pharma and Medical Device Tags: , , , , , , , , , , Comments Off on Combining Research, Safety, and Epidemiology
Read More »
« Older Entries